After U.S. Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) wrote a letter questioning price hikes of the opioid overdose treatment naloxone, John Rother, executive director of the Campaign for Sustainable Rx Pricing, released the following statement:
“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics. CSRxP will continue to tackle the problem of rising drug prices by advocating for solutions that add more transparency, competition, and value to the prescription drug market.”
In their letter, the senators highlight a recent piece from Politico which shows “at least one version of naloxone reportedly rose 17-fold in the last two years.”